Literature DB >> 20538741

Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity.

Patrick J Shaw1, Patricia E Ganey, Robert A Roth.   

Abstract

Idiosyncratic adverse drug reactions (IADRs) occur in a minority of patients yet account for the majority of postmarketing use restrictions by the Food and Drug Administration. Despite the impact of these toxicities, the underlying mechanisms are still poorly understood. Animal models of IADRs would be beneficial in understanding mechanisms and in developing assays with predictive potential. Recent work exploring the interactions between inflammatory stress and drugs associated with human idiosyncratic drug-induced liver injury (IDILI) has led to the development of the first animal models that apply to a range of drugs. Here, we discuss hypotheses for the mechanisms of IDILI and focus on a murine model of trovafloxacin-induced hepatotoxicity as an example related to the inflammatory stress hypothesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538741      PMCID: PMC2955207          DOI: 10.1093/toxsci/kfq168

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  96 in total

Review 1.  Mitochondrial abnormalities--a link to idiosyncratic drug hepatotoxicity?

Authors:  Urs A Boelsterli; Priscilla L K Lim
Journal:  Toxicol Appl Pharmacol       Date:  2006-12-22       Impact factor: 4.219

2.  Troglitazone-induced liver failure: a case study.

Authors:  David J Graham; Lanh Green; John R Senior; Parivash Nourjah
Journal:  Am J Med       Date:  2003-03       Impact factor: 4.965

3.  Bromfenac (Duract)-associated hepatic failure requiring liver transplantation.

Authors:  E B Hunter; P E Johnston; G Tanner; C W Pinson; J A Awad
Journal:  Am J Gastroenterol       Date:  1999-08       Impact factor: 10.864

Review 4.  Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor.

Authors:  Patricia E Ganey; James P Luyendyk; Jane F Maddox; Robert A Roth
Journal:  Chem Biol Interact       Date:  2004-11-01       Impact factor: 5.192

5.  Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities.

Authors:  Michie M K Ong; Calivarathan Latchoumycandane; Urs A Boelsterli
Journal:  Toxicol Sci       Date:  2006-12-05       Impact factor: 4.849

6.  A mouse model of severe halothane hepatitis based on human risk factors.

Authors:  Christine M Dugan; Allen E MacDonald; Robert A Roth; Patricia E Ganey
Journal:  J Pharmacol Exp Ther       Date:  2010-02-02       Impact factor: 4.030

7.  Bacterial- and viral-induced inflammation increases sensitivity to acetaminophen hepatotoxicity.

Authors:  Jane F Maddox; Chidozie J Amuzie; Maoxiang Li; Sandra W Newport; Erica Sparkenbaugh; Christopher F Cuff; James J Pestka; Glenn H Cantor; Robert A Roth; Patricia E Ganey
Journal:  J Toxicol Environ Health A       Date:  2010

8.  Post-halothane jaundice in relation to previous administration of halothane.

Authors:  W W Mushin; M Rosen; E V Jones
Journal:  Br Med J       Date:  1971-07-03

9.  Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity.

Authors:  Guruprasad P Aithal; Lesley Ramsay; Ann K Daly; Nhareet Sonchit; Julian B S Leathart; Graeme Alexander; J Gerald Kenna; John Caldwell; Christopher P Day
Journal:  Hepatology       Date:  2004-05       Impact factor: 17.425

10.  Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved.

Authors:  Kan He; Rasmy E Talaat; William F Pool; Michael D Reily; Jessica E Reed; Alexander J Bridges; Thomas F Woolf
Journal:  Drug Metab Dispos       Date:  2004-06       Impact factor: 3.922

View more
  35 in total

1.  Microengineered cell and tissue systems for drug screening and toxicology applications: Evolution of in-vitro liver technologies.

Authors:  O B Usta; W J McCarty; S Bale; M Hegde; R Jindal; A Bhushan; I Golberg; M L Yarmush
Journal:  Technology (Singap World Sci)       Date:  2015-03

2.  3,4-Dihydroxy-benzohydroxamic acid (Didox) suppresses pro-inflammatory profiles and oxidative stress in TLR4-activated RAW264.7 murine macrophages.

Authors:  Thabe M Matsebatlela; Amy L Anderson; Vincent S Gallicchio; Howard Elford; Charles D Rice
Journal:  Chem Biol Interact       Date:  2015-04-02       Impact factor: 5.192

3.  Screening for main components associated with the idiosyncratic hepatotoxicity of a tonic herb, Polygonum multiflorum.

Authors:  Chunyu Li; Ming Niu; Zhaofang Bai; Congen Zhang; Yanling Zhao; Ruiyu Li; Can Tu; Huifang Li; Jing Jing; Yakun Meng; Zhijie Ma; Wuwen Feng; Jinfa Tang; Yun Zhu; Jinjie Li; Xiaoya Shang; Zhengsheng Zou; Xiaohe Xiao; Jiabo Wang
Journal:  Front Med       Date:  2017-03-17       Impact factor: 4.592

Review 4.  Opportunities and challenges in the wider adoption of liver and interconnected microphysiological systems.

Authors:  David J Hughes; Tomasz Kostrzewski; Emma L Sceats
Journal:  Exp Biol Med (Maywood)       Date:  2017-05-15

Review 5.  An Update on Drug-induced Liver Injury.

Authors:  Harshad Devarbhavi
Journal:  J Clin Exp Hepatol       Date:  2012-09-21

Review 6.  Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.

Authors:  Robert J Fontana
Journal:  Gastroenterology       Date:  2013-12-31       Impact factor: 22.682

7.  Trovafloxacin potentiation of lipopolysaccharide-induced tumor necrosis factor release from RAW 264.7 cells requires extracellular signal-regulated kinase and c-Jun N-Terminal Kinase.

Authors:  Kyle L Poulsen; Ryan P Albee; Patricia E Ganey; Robert A Roth
Journal:  J Pharmacol Exp Ther       Date:  2014-02-13       Impact factor: 4.030

8.  Trovafloxacin enhances lipopolysaccharide-stimulated production of tumor necrosis factor-α by macrophages: role of the DNA damage response.

Authors:  Kyle L Poulsen; Jesus Olivero-Verbel; Kevin M Beggs; Patricia E Ganey; Robert A Roth
Journal:  J Pharmacol Exp Ther       Date:  2014-05-09       Impact factor: 4.030

9.  In vitro models for liver toxicity testing.

Authors:  Valerie Y Soldatow; Edward L Lecluyse; Linda G Griffith; Ivan Rusyn
Journal:  Toxicol Res (Camb)       Date:  2012-11-23       Impact factor: 3.524

10.  Nonalcoholic Fatty Liver Disease Is a Susceptibility Factor for Perchloroethylene-Induced Liver Effects in Mice.

Authors:  Joseph A Cichocki; Shinji Furuya; Yu-Syuan Luo; Yasuhiro Iwata; Kranti Konganti; Weihsueh A Chiu; David W Threadgill; Igor P Pogribny; Ivan Rusyn
Journal:  Toxicol Sci       Date:  2017-09-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.